Using germfree animal models to prove the role of the gut microbiota in liver diseases

Dr. Philippe Gérard from INRA, France will talk about "Using germfree animal models to prove the role of the gut microbiota in liver diseases" during  6th World Congress on Targeting Microbiota 2018 Congress which will be held in October 28-30, 2018, at Porto, Portugal.

Summary of talk: The portal vein conducts blood from the gastrointestinal tract to the liver which is thus one of the main organ that can be influenced by microbiome composition and activities. Nonalcoholic and alcoholic fatty liver disease (NAFLD and ALD, respectively) refers to a spectrum of liver damage ranging from simple steatosis to non-alcoholic steatohepatitis, advanced fibrosis, cirrhosis or even hepatocellular carcinoma. Using microbiota transplants from conventional mice or human alcoholic patients to germ-free mice, we demonstrated that the gut microbiota determines development of NAFLD and that the individual susceptibility to ALD may be driven by intestinal bacteria. This suggests that targeting the gut microbiota could be a new prevention or therapeutic approach for liver diseases management.

For more information: www.microbiota-site.com